Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution

Vox Sanguinis ◽  
2015 ◽  
Vol 110 (3) ◽  
pp. 244-252 ◽  
Author(s):  
A. A. Ignatova ◽  
O. V. Karpova ◽  
P. E. Trakhtman ◽  
S. A. Rumiantsev ◽  
M. A. Panteleev
Keyword(s):  
Ultraviolet Light ◽  
Clinical Effectiveness ◽  
Platelet Concentrates ◽  
Functional Characteristics ◽  
Additive Solution

scholarly journals Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

2010 ◽  
pp. no-no ◽  
Author(s):  
Jean-Louis H. Kerkhoffs ◽  
Wim L. J. Van Putten ◽  
Viera M. J. Novotny ◽  
Peter A.W. Te Boekhorst ◽  
Martin R. Schipperus ◽  
...  
Keyword(s):  
Clinical Effectiveness ◽  
Platelet Concentrates ◽  
Pathogen Reduction ◽  
Additive Solution

In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution

Vox Sanguinis ◽  
2007 ◽  
Vol 0 (0) ◽  
pp. 071127145052002-??? ◽  
Author(s):  
B. Diedrich ◽  
P. Sandgren ◽  
B. Jansson ◽  
H. Gulliksson ◽  
L. Svensson ◽  
...  
Keyword(s):  
Platelet Concentrates ◽  
Additive Solution ◽  
In Vivo Effects

scholarly journals Comparison of harvesting methods and clinical application of apheresis platelet concentrates with additive solution

2015 ◽  
Vol 10 (2) ◽  
pp. 63
Author(s):  
O. V. Karpova ◽  
I. V. Obraztsov ◽  
P. E. Trakhtman ◽  
A. A. Ignatova ◽  
M. A. Panteleev ◽  
...  
Keyword(s):  
Clinical Application ◽  
Platelet Concentrates ◽  
Additive Solution

scholarly journals Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light

Transfusion ◽  
2005 ◽  
Vol 45 (4) ◽  
pp. 580-590 ◽  
Author(s):  
Lily Lin ◽  
Carl V. Hanson ◽  
Harvey J. Alter ◽  
Valérie Jauvin ◽  
Kristen A. Bernard ◽  
...  
Keyword(s):  
Ultraviolet Light ◽  
Platelet Concentrates ◽  
Long Wavelength

Inactivation ofPlasmodiumspp. in plasma and platelet concentrates using riboflavin and ultraviolet light

Transfusion ◽  
2013 ◽  
pp. n/a-n/a ◽  
Author(s):  
Shawn D. Keil ◽  
Patti Kiser ◽  
James J. Sullivan ◽  
Amy S. Kong ◽  
Heather L. Reddy ◽  
...  
Keyword(s):  
Ultraviolet Light ◽  
Platelet Concentrates

Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study

Transfusion ◽  
2000 ◽  
Vol 40 (4) ◽  
pp. 398-403 ◽  
Author(s):  
J. de Wildt-Eggen ◽  
S. Nauta ◽  
J.G. Schrijver ◽  
M. van Marwijk Kooy ◽  
M. Bins ◽  
...  
Keyword(s):  
Randomized Study ◽  
Prospective Randomized Study ◽  
Platelet Concentrates ◽  
Additive Solution

Leucocyte-Reduced Buffy Coat Platelet Concentrates (BCPC) Treated with INTERCEPT™ Stored up to 7 Days: Hemostatic Function in a Whole Blood Flow System.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 956-956
Author(s):  
Miguel Lozano ◽  
Ana Galan ◽  
Roberto Mazzara ◽  
Laurence Corash ◽  
Gines Escolar
Keyword(s):  
Blood Flow ◽  
Platelet Count ◽  
Whole Blood ◽  
Flow System ◽  
Ex Vivo ◽  
Buffy Coat ◽  
Platelet Concentrates ◽  
Platelet Storage ◽  
Pre Treatment ◽  
Additive Solution

Abstract Background: The risk of bacterial growth has limited the shelf life of platelet concentrates (PC) to 5 days. Modern platelet storage containers facilitate storage for up to 7 days, if bacterial contamination is prevented. INTERCEPT (Baxter, La Chatre, France; Cerus, Concord, CA) photochemical treatment (PCT) for pathogen reduction based on amotosalen (150μM) and UVA illumination (3 J/cm2) inactivates high titers of bacteria in PC (Transfusion2004; 44: 1496–1504). Adhesion and aggregation of platelets to injured vascular surfaces are critical aspects of platelet hemostatic function. In this study, the adhesion and aggregation of leucocyte-reduced buffy coat derived PC (BCPC), treated with INTERCEPT and stored up to 7 days, were measured on injured vascular surfaces using an ex-vivo blood flow system. Methods: BCPC were prepared from 450 mL-whole blood donations with the top and bottom method (Optipress II, Baxter). Five BCPC, of the same ABO group, were pooled with additive solution (Intersol™) the day following collection, after viral screening testing was completed. Following centrifugation and leukocyte depletion, two BCPC pools of the same ABO group were mixed and divided. One pooled BCPC was treated with INTERCEPT (I-BCPC) and the other was prepared by conventional methods (C-BCPC); and both were stored in 1.3 liter PL2410 plastic containers (Baxter R4R7012) at 22 ± 2°C with continuous agitation for 7 days. Samples for hemostatic function testing were taken immediately after preparation before splitting for treatment and after 5 and 7 days of storage. Platelet counts were performed in K3EDTA in a Coulter MD II counter (Coulter, Miami, FL). Samples of I-BCPC and C-BCPC were added to citrate anticoagulated blood, previously depleted of platelets and leukocytes by filtration, and adjusted to a final platelet count of 150x109/L. Enzymatically denuded vascular segments were exposed to circulating whole blood, reconstituted with I-BCPC and C-BCPC, in Baumgartner chambers at a shear rate of 800 s−1 for 10 minutes. The proportion (%) of the vascular surface area covered by platelets after perfusion was measured for each type of BCPC (N = 9) at each storage time point. Platelets and groups of platelets were classified as adhesive when platelet masses were less than 5 μm in height and as thrombi when height exceeded 5 μm. Data were analyzed with the SPSS 12.0.1 statistical package with significance at p < 0.05, and expressed at the mean ± SEM Results(Table). Conclusion: The platelet count of I- BCPC decreased by 12.3% including PCT processing losses and 7 days of storage. However, I- BCPC platelet adhesive and aggregatory capacities under flow conditions were similar to C- BCPC, and were well conserved for up to 7 days of storage. Hemostatic Function of Stored I-BCPC and C-BCPC Parameter I-BCPC C-BCPC p Day 1(Pre Treatment) Platelet Count (109/L) 945±40 945±40 Platelet Coverage (%) 26.0±3.7 26.0±4.2 Adhesion(%) 24.0±3.7 24.0±3.7 Thrombus(%) 1.9±0.6 1.9±0.6 Day 5 Storage Platelet Count (109/L 844±41 902±44 0.004 Platelet Coverage (%) 20.9±2.2 20.6±1.6 0.9 Adhesion(%) 19.9±2.1 19.3±1.4 0.8 Thrombus(%) 0.9±0.3 1.2±0.4 0.5 Day 7 Storage Platelet Count (109/L) 829±32 923±48 0.008 Platelet Coverage (%) 27.1±2.9 21.2±2.8 0.06 Adhesion(%) 26.0±2.7 20.4±2.7 0.06 Thrombus(%) 1.2±0.3 0.7±0.2 0.16

Sign in / Sign up

Export Citation Format

Share Document